Pathogens (Dec 2023)

Anti-Hcp1 Monoclonal Antibody Is Protective against <i>Burkholderia pseudomallei</i> Infection via Recognizing Amino Acids at Asp95-Leu114

  • Pan Wu,
  • Chenglong Rao,
  • Wenzheng Liu,
  • Ziyuan Zhang,
  • Dongqi Nan,
  • Jiangao Chen,
  • Minyang Wang,
  • Yuan Wen,
  • Jingmin Yan,
  • Juanjuan Yue,
  • Xuhu Mao,
  • Qian Li

DOI
https://doi.org/10.3390/pathogens13010043
Journal volume & issue
Vol. 13, no. 1
p. 43

Abstract

Read online

Melioidosis, a severe tropical illness caused by Burkholderia pseudomallei, poses significant treatment challenges due to limited therapeutic options and the absence of effective vaccines. The pathogen’s intrinsic resistance to numerous antibiotics and propensity to induce sepsis during acute infections further complicate management strategies. Thus, exploring alternative methods for prevention and treatment is crucial. Monoclonal antibodies (mAbs) have emerged as a promising strategy for the prevention and treatment of infectious diseases. This study focused on generating three mAbs (13F1, 14G11, and 15D9) targeting hemolysin-coregulated protein 1 (Hcp1), a protein involved in the type VI secretion system cluster 1 (T6SS1) of B. pseudomallei. Notably, pretreatment with 13F1 mAb significantly reduced the intracellular survival of B. pseudomallei and inhibited the formation of macrophage-derived multinucleated giant cells (MNGCs). This protective effect was also observed in vivo. We identified a sequence of amino acids (Asp95-Leu114) within Hcp1 as the likely binding site for 13F1 mAb. In summary, our findings reveal that 13F1 mAb counteracts infection by targeting Hcp1, offering potential new targets and insights for melioidosis prevention.

Keywords